Caplin Steriles, the subsidiary of Caplin Point Laboratories, has received final approval from the United States Food and Drug Administration (USFDA) for its Desmopressin Acetate Injection USP. The approval covers both 4 mcg/mL single-dose vials and 40 mcg/10 mL (4 mcg/mL) multiple-dose vials.
The product is a generic therapeutic equivalent of the reference drug DDAVP (desmopressin acetate) Injection developed by Nordic Pharma Inc. The approval was granted through the Abbreviated New Drug Application (ANDA) pathway, which allows companies to market lower-cost generic versions once regulatory standards are met.
Desmopressin Acetate Injection is an important medicine used in the treatment of haemophilia A, von Willebrand disease, and central diabetes insipidus. It helps control bleeding in certain patients and also supports the body in regulating urine production. Because of these uses, the drug plays a meaningful role in hospital and specialty care settings.
According to IQVIA (IMS Health) data, the US market for this injection recorded sales of about $26 million for the 12-month period ending December 2025. This indicates a modest but steady commercial opportunity for generic manufacturers entering the segment.
For Caplin Steriles, the approval strengthens its growing presence in the regulated US market. The company has been focusing on expanding its injectable portfolio and building a pipeline of complex generics. Regulatory clearances such as this one support its strategy of increasing product offerings and improving market reach.
Investors and industry watchers will now look at how quickly the company commercializes the product and captures market share. Pricing strategy, supply reliability, and hospital adoption will be key factors in determining the financial impact.
Overall, the USFDA approval marks another step forward for Caplin Steriles as it continues to expand its footprint in specialty injectable medicines in the United States.
